Retinopathy of prematurity: An epidemic in the making

Chinese Medical Journal

Volumn 123, Issue 20, 2010, Pages 2929-2937

  Quinn, Graham E ^a   Gilbert, Clare ^b   Darlow, Brian A ^c   Zin, Andrea ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Blindness; Childhood; Premature birth; Retinopathy of prematurity

Indexed keywords

CORTICOSTEROID; SOMATOMEDIN C; VASCULOTROPIN INHIBITOR; VASCULOTROPIN A;

ABLATION THERAPY; BIRTH WEIGHT; BLINDNESS; CRYOTHERAPY; DATA BASE; DISEASE CLASSIFICATION; EPIDEMIC; GENETIC ASSOCIATION; HEALTH SERVICE; HUMAN; INCIDENCE; LASER COAGULATION; MORBIDITY; MORTALITY; NEWBORN; NEWBORN CARE; OBSTETRIC PROCEDURE; OXYGEN SATURATION; PREMATURE LABOR; PRENATAL CARE; PREVALENCE; RETINA DETACHMENT; RETROLENTAL FIBROPLASIA; REVIEW; SEPSIS; TELEMEDICINE; WEIGHT GAIN; CLASSIFICATION; DRUG ANTAGONISM; PHYSIOLOGY;

HUMANS; INCIDENCE; INFANT, NEWBORN; INSULIN-LIKE GROWTH FACTOR I; PREVALENCE; RETINOPATHY OF PREMATURITY; SEPSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952277093     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.20.033     Document Type: Review

References (110)

1. Patz A. Retrolental fibroplasia. Surv Ophthalmol 1969; 14: 1-29.
2. Patz A. The role of oxygen in retrolental fibroplasia. Albrecht Von Graefe's Arch Clin Exp Ophthalmol 1975; 195: 77-85.
3. Patz A. Clinical and experimental studies on role of oxygen in retrolental fibroplasia. Trans Am Acad O&O 1954; 58: 45-50.
4. Patz A, Hoeck LE, De La Cruz E. Studies on the effect of high oxygen administration in retrolental fibroplasia. I. Nursery observations. Am J Ophthalmol 1952; 35: 1248-1252.
5. Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia: a clinical approach. Med J Australia 1951; 2: 48-50.
6. Flynn JT, Bancalari E, Snyder ES, Goldberg RN, Feuer W, Cassady J, et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med 1992; 326: 1050-1054.
7. Jonathan TL, Loren PG, Joseph D. Retrolental fibroplasia and oxygen therapy. J Am Med Assoc 1954; 155: 223-226.
8. Cross CW. Cost of preventing retrolental fibroplasia. Lancet 1973; 2: 954-956.
9. Gibson DL, Sheps SB, Schechter MT, Wiggins S, McCormick AQ. Retinopathy of prematurity: a new epidemic? Pediatrics 1989; 83: 486-492.
10. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Pediatrics 1988; 81: 697-706.
11. Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, et al; Cryotherapy for Retinopathy of Prematurity Cooperative Group. Incidence and early course of retinopathy of prematurity. Ophthalmology 1991; 98: 1628-1640.
12. Good WV, Hardy RA, Dobson V, Palmer EA, Phelps DL, Quintos M, et al; Early Treatment for Retinopathy of Prematurity Cooperative Group. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics 2005; 116: 15-23.
13. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003; 121: 1684-1694.
14. Gilbert CE, Anderton L, Dandona L, Foster A. Prevalence of visual impairment in children: a review of available data. Ophthalmic Epidemiol 1999; 6: 73-82.
15. Gilbert C, Foster A. Childhood blindness in the context of VISION 2020-the right to sight. Bull World Health Organ 2001; 79: 227-232.
16. Gilbert C, Fielder A, Gordillo L, Quinn G, Semiglia R, Visintin P, et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 2005; 115: e518-e525.
17. Gilbert C, Rahi J, Eckstein M, O'Sullivan J, Foster A. Retinopathy of prematurity in middle-income countries. Lancet 1997; 350: 12-14.
18. Chen Y, Li X. Characteristics of severe retinopathy of prematurity patients in China: a repeat of the first epidemic? Br J Ophthalmol 2006; 90: 268-271.
19. Phan MH, Nguyen PN, Reynolds JD. Incidence and severity of retinopathy of prematurity in Vietnam, a developing middle-income country. J Pediatr Ophthalmol Strabismus 2003; 40: 208-212.
20. Azad RV, Chandra P. Retinopathy of prematurity - screening and management. J Indian Med Assoc 2003; 101: 593-596.
21. Jalali S, Anand R, Kumar H, Dogra MR, Azad R, Gopal L. Programme planning and screening strategy in retinopathy of prematurity. Indian J Ophthalmol 2003; 51: 89-99.
22. Lermann VL, Fortes Filho JB, Procianoy RS. The prevalence of retinopathy of prematurity in very low birth weight newborn infants. J Pediatr (Rio J) 2006; 82: 27-32.
23. Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008; 84: 77-82.
24. International Committee for the Classification of ROP. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005; 123: 991-999.
25. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 1988; 106: 471-479.
26. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome - structure and function. Arch Ophthalmol 1990; 108: 1408-1416.
27. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Three-month outcome. Arch Ophthalmol 1990; 108: 195-204.
28. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. 3 1/2-year outcome-structure and function. Arch Ophthalmol 1993; 111: 339-344.
29. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Snellen visual acuity and structural outcome at 5 1/2 years after randomization. Arch Ophthalmol 1996; 114: 417-424.
30. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of Prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol 2001; 119: 1110-1118.
31. Palmer EA, Hardy RJ, Dobson V, Phelps DL, Quinn GE, Summers CG, et al; Cryotherapy for Retinopathy of Prematurity Cooperative Group. 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol 2005; 123: 311-318.
32. Palmer EA, Hardy RJ, Dobson V, Phelps DL, Quinn GE, Summers CG, et al; Cryotherapy for Retinopathy of Prematurity Cooperative Group. Risk analysis of prethreshold retinopathy of prematurity. Arch Ophthalmol 2003; 121: 1697-1701.
33. McNamara JA. Laser treatment for retinopathy of prematurity. Curr Opin Ophthalmol 1993; 4: 76-80.
34. Bressler SB. Laser therapy for retinopathy of prematurity. Arch Ophthalmol 1995; 113: 137.
35. Foroozan R, Connolly BP, Tasman WS. Outcomes after laser therapy for threshold retinopathy of prematurity. Ophthalmology 2001; 108: 1644-1646.
36. Trese M. Scleral buckling for retinopathy of prematurity. Ophthalmology1994; 101: 23-26.
37. Andrews AP, Hartnett ME, Hirose T. Surgical advances in retinopathy of prematurity. Int Ophthalmol Clin 1999; 39: 275-290.
38. Hirose T, Katsumi O, Mehta MC, Schepens CL. Vision in stage 5 retinopathy of prematurity after retinal reattachment by open-sky vitrectomy. Arch Ophthalmol 1993; 111: 345-349.
39. Jabbour NM, Eller AE, Hirose T, Schepens CL, Liberfarb R. Stage 5 retinopathy of prematurity. Prognostic value of morphologic findings. Ophthalmology 1987; 94: 1640-1646.
40. Quinn GE, Dobson V, Barr CC, Davis BR, Palmer EA, Robertson J, et al. Visual acuity of eyes after vitrectomy for retinopathy of prematurity: follow-up at 5 1/2 years. Ophthalmology 1996; 103: 595-600.
41. Quinn GE, Dobson V, Barr CC, Davis BR, Flynn JT, Palmer EA, et al. Visual acuity in infants after vitrectomy for severe retinopathy of prematurity. Ophthalmology 1991; 98: 5-13.
42. Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, et al. Incidence and early course of retinopathy of prematurity. Ophthalmology 1991; 98: 1628-1640.
43. Reynolds JD, Dobson V, Quinn GE, Fielder AR, Palmer EA, Saunders RA, et al; CRYO-ROP and LIGHT-ROP Cooperative Study Groups. Evidence-based screening criteria for retinopathy of prematurity: natural history data from the CRYO-ROP and LIGHT-ROP studies. Arch Ophthalmol 2002; 120: 1470-1476.
44. Fielder AR, Shaw DE, Robinson J, Ng YK. Natural history of retinopathy of prematurity: a prospective study. Eye (Lond) 1992; 6: 233-242.
45. Repka MX, Palmer EA, Tung B. Involution of retinopathy of prematurity. Cryotherapy for retinopathy of prematurity cooperative group. Arch Ophthalmol 2000; 118: 645-649.
46. Dobson V, Quinn GE, Tung B, Palmer EA, Reynolds JD. Comparison of recognition and grating acuities in very-low-birth-weight children with and without retinal residua of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1995; 36: 692-702.
47. Gilbert WS, Dobson V, Quinn GE, Reynolds J, Tung B, Flynn JT. The correlation of visual function with posterior retinal structure in severe retinopathy of prematurity. Arch Ophthalmol 1992; 110: 625-631.
48. Gilbert WS, Dobson V, Quinn GE, Reynolds J, Tung B, Flynn JT. The correlation of visual function with posterior retinal structure in severe retinopathy of prematurity. Arch Ophthalmol 1992; 110: 625-631.
49. Gilbert WS, Quinn GE, Dobson V, Reynolds J, Hardy RJ, Palmer EA. Partial retinal detachment at 3 months after threshold retinopathy of prematurity. Long-term structural and functional outcome. Arch Ophthalmol 1996; 114: 1085-1091.
50. Reynolds J, Dobson V, Quinn GE, Gilbert WS, Tung B, Robertson J, et al. Prediction of visual function in eyes with mild to moderate posterior pole residua of retinopathy of prematurity. Arch Ophthalmol 1993; 111: 1050-1056.
51. Darlow BA, Horwood LJ, Clemett RS. Retinopathy of prematurity: risk factors in a prospective population-based study. Paediatr Perinat Epidemiol 1992; 6: 62-80.
52. Darlow BA, Hutchinson JL, Henderson-Smart DJ, Donoghue DA, Simpson JM, Evans NJ; Australian and New Zealand Neonatal Network. Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. Pediatrics 2005; 115: 990-996.
53. Section on Ophthalmology American Academy of Pediatrics; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2006; 117: 572-576.
54. Royal College of Paediatrics and Child Health, Royal College of Ophthalmologists, British Association of Perinatal Medicine. The guideline for screening and treatment of retinopathy of prematurity. (Accessed May 1, 2008 at www.rcpch.ac.uk/research/ce/rcpch-guidelines/ROP).
55. Varughese S, Gilbert C, Pieper C, Cook C. Retinopathy of prematurity in South Africa: an assessment of needs, resources and requirements for screening programmes. Br J Ophthalmol 2008; 92: 879-882.
56. Vedantham V. Retinopathy of prematurity screening in the Indian population: it's time to set our own guidelines. Indian J Ophthalmol 2007; 55: 329-330.
57. Fortes Filho JB, Barros CK, da Costa MC, Procianoy RS. Results of a program for the prevention of blindness caused by retinopathy of prematurity in southern Brazil. J Pediatr (Rio J) 2007; 83: 209-216.
58. Trinavarat A, Atchaneeyasakul LO, Udompunturak S. Applicability of American and British criteria for screening of the retinopathy of prematurity in Thailand. Jpn J Ophthalmol 2004; 48: 50-53.
59. Zin A, Moreira MEL, Bunce C. Screening for retinopathy of prematurity in seven neonatal units in Rio de Janeiro, Brazil: criteria and workload implications: a tale of two cities? Pediatrics 2010; 126: e410-e417.
60. Cole CH, Wright KW, Tarnow-Mordi W, Phelps DL; Pulse Oximetry Saturation Trial for Prevention of Retinopathy of Prematurity Planning Study Group. Resolving our uncertainty about oxygen therapy. Pediatrics 2003; 112: 1415-1419.
61. The STOP-ROP Multicenter Study Group. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes (see comments). Pediatrics 2000; 105: 295-310.
62. Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM. Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med 2003; 349: 959-967.
63. Tin W, Milligan DW, Pennefather P, Hey E. Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child Fetal Neonatal Ed 2001; 84: F106-F110.
64. Chow LC, Wright KW, Sola A; CSMC Oxygen Administration Study Group. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? Pediatrics 2003; 111: 339-345.
65. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Carlo WA, Finer NN, Walsh MC, Rich W, Gantz MG, et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med 2010; 362: 1959-1969.
66. Chaudhari S, Patwardhan V, Vaidya U, Kadam S, Kamat A. Retinopathy of prematurity in a tertiary care center-incidence, risk factors and outcome. Indian Pediatr 2009; 46: 219-224.
67. Sears JE, Pietz J, Sonnie C, Dolcini D, Hoppe G. A change in oxygen supplementation can decrease the incidence of retinopathy of prematurity. Ophthalmology 2009; 116: 513-518.
68. Sola A, Saldeno YP, Favareto V. Clinical practices in neonatal oxygenation: where have we failed? What can we do? J Perinatol 2008; 28 Suppl 1: S28-S34.
69. Wallace DK, Veness-Meehan KA, Miller WC. Incidence of severe retinopathy of prematurity before and after a modest reduction in target oxygen saturation levels. J AAPOS 2007; 11: 170-174.
70. Tin W, Gupta S. Optimum oxygen therapy in preterm babies. Arch Dis Child Fetal Neonatal Ed 2007; 92: F143-F147.
71. Vanderveen DK, Mansfield TA, Eichenwald EC. Lower oxygen saturation alarm limits decrease the severity of retinopathy of prematurity. J AAPOS 2006; 10: 445-448.
72. Tin W, Walker S, Lacamp C. Oxygen monitoring in preterm babies: too high, too low? Paediatr Respir Rev 2003; 4: 9-14.
73. Klinger G, Levy I, Sirota L, Boyko V, Lerner-Geva L, Reichman B; in collaboration with the Israel Neonatal Network. Outcome of early-onset sepsis in a national cohort of very low birth weight infants. Pediatrics 2010; 125: e736-e740.
74. Manzoni P, Rinaldi M, Cattani S, Pugni L, Romeo MG, Messner H, et al; Italian Task Force for the Study and Prevention of Neonatal Fungal Infections, Italian Society of Neonatology. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA 2009; 302: 1421-1428.
75. Lofqvist C, Chen J, Connor KM, Smith AC, Aderman CM, Liu N, et al. IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci USA 2007; 104: 10589-10594.
76. Löfqvist C, Andersson E, Sigurdsson J, Engström E, Hård AL, Niklasson A, et al. Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol 2006; 124: 1711-1718.
77. Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A 2001; 98: 5804-5808.
78. Hellström A, Engström E, Hård AL, Albertsson-Wikland K, Carlsson B, Niklasson A, et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003; 112: 1016-1020.
79. Löfqvist C, Hansen-Pupp I, Andersson E, Holm K, Smith LE, Ley D, et al. Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulinlike growth factor I. Arch Ophthalmol 2009; 127: 622-627.
80. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis 2007; 10: 133-140.
81. Heidary G, Vanderveen D, Smith LE. Retinopathy of prematurity: current concepts in molecular pathogenesis. Semin Ophthalmol 2009; 24: 77-81.
82. Löfqvist C, Niklasson A, Engström E, Friberg LE, Camacho-Hübner C, Ley D, et al. A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm Infants. Pediatr Res 2009; 65: 574-579.
83. Mantagos IS, Vanderveen DK, Smith LE. Emerging treatments for retinopathy of prematurity. Semin Ophthalmol 2009; 24: 82-86.
84. Kwinta P, Pietrzyk JJ. Retinopathy of prematurity: is genetic predisposition an important risk factor? Expert Review of Ophthalmology 2007; 2: 275-283
85. Holmström G, van Wijngaarden P, Coster DJ, Williams KA. Genetic susceptibility to retinopathy of prematurity: the evidence from clinical and experimental animal studies. Br J Ophthalmol 2007; 91: 1704-1708.
86. Ells AL, Holmes JM, Astle WF, Williams G, Leske DA, Fielden M, et al. Telemedicine approach to screening for severe retinopathy of prematurity: a pilot study. Ophthalmology 2003; 110: 2113-2117.
87. Shah DN, Karp KA, Ying GS, Mills MD, Quinn GE. Image analysis of posterior pole vessels identifies type 1 retinopathy of prematurity. J AAPOS 2009; 13: 507-508.
88. Shah DN, Wilson CM, Ying GS, Karp KA, Fielder AR, Ng J, et al. Semiautomated digital image analysis of posterior pole vessels in retinopathy of prematurity. J AAPOS 2009; 13: 504-506.
89. Grunwald L, Mills MD, Johnson KS, Karp KA, Quinn GE, Ying GS, et al. The rate of retinal vessel dilation in severe retinopathy of prematurity requiring treatment. Am J Ophthalmol 2009; 147: 1086-1091.
90. Wallace DK, Jomier J, Aylward SR, Landers MB 3rd. Computer-automated quantification of plus disease in retinopathy of prematurity. J AAPOS 2003; 7: 126-130.
91. Yanovitch TL, Freedman SF, Wallace DK. Vascular dilation and tortuosity in plus disease. Arch Ophthalmol 2009; 127: 112-113.
92. Wilson CM, Cocker KD, Moseley MJ, Paterson C, Clay ST, Schulenburg WE, et al. Computerized analysis of retinal vessel width and tortuosity in premature infants. Invest Ophthalmol Vis Sci 2008; 49: 3577-3585.
93. Johnson KS, Mills MD, Karp KA, Grunwald JE. Quantitative analysis of retinal vessel diameter reduction after photocoagulation treatment for retinopathy of prematurity. Am J Ophthalmol 2007; 143: 1030-1032.
94. Chiang MF, Starren J, Du YE, Keenan JD, Schiff WM, Barile GR, et al. Remote image based retinopathy of prematurity diagnosis: a receiver operating characteristic analysis of accuracy. Br J Ophthalmol 2006; 90: 1292-1296.
95. Chiang MF, Wang L, Busuioc M, Du YE, Chan P, Kane SA, et al. Telemedical retinopathy of prematurity diagnosis: accuracy, reliability, and image quality. Arch Ophthalmol 2007; 125: 1531-1538.
96. Skalet AH, Quinn GE, Ying GS, Gordillo L, Dodobara L, Cocker K, et al. Telemedicine screening for retinopathy of prematurity in developing countries using digital retinal images: a feasibility project. J AAPOS 2008; 12: 252-258.
97. Campbell PB, Bull MJ, Ellis FD, Bryson CQ, Lemons JA, Schreiner RL. Incidence of retinopathy of prematurity in a tertiary newborn intensive care unit. Arch Ophthalmol 1983; 101: 1686-1688.
98. Lorenz B, Bock M, Müller HM, Massie NA. Telemedicine based screening of infants at risk for retinopathy of prematurity. Stud Health Technol Inform 1999; 64: 155-163.
99. Photographic Screening for Retinopathy of Prematurity (Photo-ROP) Cooperative Group, Balasubramanian M, Capone A Jr, Hartnett ME, Pignatto S, Trese MT. The Photographic Screening for Retinopathy of Prematurity Study (Photo-ROP): study design and baseline characteristics of enrolled patients. Retina 2006; 26 (7 Suppl): S4-S10.
100. Photographic Screening for Retinopathy of Prematurity (Photo-ROP) Cooperative Group. The photographic screening for retinopathy of prematurity study (photo-ROP). Primary outcomes. Retina 2008; 28 (3 Suppl): S47-S54.
101. Kemper AR, Wallace DK, Quinn GE. Response to letter to editor: systematic review of digital imaging screening strategies for retinopathy of prematurity: in reply. Pediatrics 2009; 123: e360-e361.
102. Kemper AR, Wallace DK, Quinn GE. Systematic review of digital imaging screening strategies for retinopathy of prematurity. Pediatrics 2008; 122: 825-830.
103. Fielder A, Hildebrand P, Ells A. Letter to editor: systematic review of digital imaging screening strategies for retinopathy of prematurity. Pediatrics 2009; 123: e360-e361.
104. Thebaud B, Abman SH. Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am J Respir Crit Care Med 2007; 175: 978-985.
105. Rosenstein JM, Krum JM. New roles for VEGF in nervous tissue-beyond blood vessels. Exp Neurol 2004; 187: 246-253
106. Mintz-Hittner HA, Best LM. Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Pediatr 2009; 21: 182-7.
107. Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008; 28: 831-838.
108. Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008; 28 (3 Suppl): S19-S25.
109. Darlow BA, Gilbert C, Quinn GE. Promise and potential pitfalls of anti-VEGF drugs in retinopathy of prematurity. Br J Ophthalmol 2009; 93: 986.
110. Revisited International Committee for ROP. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005; 123: 991-999.